These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Two Doses of BNT162b2 mRNA Vaccine in Patients after Hematopoietic Stem Cell Transplantation: Humoral Response and Serological Conversion Predictors. Majcherek M; Matkowska-Kocjan A; Szymczak D; Karasek M; Szeremet A; Kiraga A; Milanowska A; Kuznik E; Kujawa K; Wrobel T; Szenborn L; Czyz A Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053487 [TBL] [Abstract][Full Text] [Related]
44. Effect of COVID-19 on Anti-S Antibody Response in Healthcare Workers Six Months Post-Vaccination. Flisiak R; Pawłowska M; Rogalska-Płońska M; Bociąga-Jasik M; Kłos K; Piekarska A; Zarębska-Michaluk D Vaccines (Basel); 2021 Nov; 9(11):. PubMed ID: 34835257 [TBL] [Abstract][Full Text] [Related]
45. Aspects of Humoral Immunity after Vaccination with Bnt162b2: A Small Study. Giubelan LI; Dumitrescu F; Dragonu L; Stoian AC; Ilie C; Stanciu I Curr Health Sci J; 2022; 48(1):24-28. PubMed ID: 35911947 [TBL] [Abstract][Full Text] [Related]
46. COVID-19 mRNA Based Vaccine Immune-Response Assessment in Nursing Home Residents for Public Health Decision. San Segundo D; Comins-Boo A; Lamadrid-Perojo P; Irure-Ventura J; Castillo-Otí JM; Wallman R; Calvo-Montes J; Méndez-Legaza JM; Baamonde-Calzada C; Sánchez-Molina I; Lecue-Martínez M; Ventisca-Pérez S; Batlle-López A; Hoyos ML Vaccines (Basel); 2021 Dec; 9(12):. PubMed ID: 34960173 [TBL] [Abstract][Full Text] [Related]
47. Serum Level of Anti-Nucleocapsid, but Not Anti-Spike Antibody, Is Associated with Improvement of Long COVID Symptoms. Varnai R; Molnar T; Zavori L; Tőkés-Füzesi M; Illes Z; Kanizsai A; Csecsei P Vaccines (Basel); 2022 Jan; 10(2):. PubMed ID: 35214624 [TBL] [Abstract][Full Text] [Related]
48. Attenuation of Antibody Titers from 3 to 6 Months after the Second Dose of the BNT162b2 Vaccine Depends on Sex, with Age and Smoking Risk Factors for Lower Antibody Titers at 6 Months. Nomura Y; Sawahata M; Nakamura Y; Koike R; Katsube O; Hagiwara K; Niho S; Masuda N; Tanaka T; Sugiyama K Vaccines (Basel); 2021 Dec; 9(12):. PubMed ID: 34960246 [TBL] [Abstract][Full Text] [Related]
49. Determining the best window for BNT162b2 mRNA vaccination for SARS-CoV-2 in patients with multiple sclerosis receiving anti-CD20 therapy. Rico A; Ninove L; Maarouf A; Boutiere C; Durozard P; Demortiere S; Saba Villarroel PM; Amroun A; Fourié T; de Lamballerie X; Pelletier J; Audoin B Mult Scler J Exp Transl Clin; 2021 Oct; 7(4):20552173211062142. PubMed ID: 34925877 [TBL] [Abstract][Full Text] [Related]
50. Assessing the Reliability of SARS-CoV-2 Neutralization Studies That Use Post-Vaccination Sera. Jacobsen H; Sitaras I; Jurgensmeyer M; Mulders MN; Goldblatt D; Feikin DR; Bar-Zeev N; Higdon MM; Knoll MD Vaccines (Basel); 2022 May; 10(6):. PubMed ID: 35746460 [TBL] [Abstract][Full Text] [Related]
51. High Concentration of Anti-SARS-CoV-2 Antibodies 2 Years after COVID-19 Vaccination Stems Not Only from Boosters but Also from Widespread, Often Unrecognized, Contact with the Virus. Swadźba J; Panek A; Wąsowicz P; Anyszek T; Martin E Vaccines (Basel); 2024 Apr; 12(5):. PubMed ID: 38793722 [TBL] [Abstract][Full Text] [Related]
52. COVID-19 Antibody Seroconversion in Cancer Patients: Impact of Therapy Cessation-A Single-Center Study. Souan L; Abdel-Razeq H; Nashwan S; Al Badr S; Alrabi K; Sughayer MA Vaccines (Basel); 2023 Oct; 11(11):. PubMed ID: 38005991 [TBL] [Abstract][Full Text] [Related]
53. Lack of vitamin D predicts impaired long-term immune response to COVID-19 vaccination. di Filippo L; Frara S; Terenzi U; Nannipieri F; Locatelli M; Ciceri F; Giustina A Endocrine; 2023 Dec; 82(3):536-541. PubMed ID: 37592162 [TBL] [Abstract][Full Text] [Related]
54. Evaluation of Antibody Kinetics Following COVID-19 Vaccination in Greek SARS-CoV-2 Infected and Naïve Healthcare Workers. Pavlidis G; Giannoulis V; Pirounaki M; Lampropoulos IC; Siafi E; Nitsa A; Pavlou E; Xanthaki A; Perlepe G; Fortis SP; Charalambous G; Kampolis CF; Pantazopoulos I J Pers Med; 2023 May; 13(6):. PubMed ID: 37373899 [TBL] [Abstract][Full Text] [Related]
55. SARS-CoV-2 Breakthrough Infections According to the Immune Response Elicited after mRNA Third Dose Vaccination in COVID-19-Naïve Hospital Personnel. Santoro A; Capri A; Petrone D; Colavita F; Meschi S; Matusali G; Mizzoni K; Notari S; Agrati C; Goletti D; Pezzotti P; Puro V Biomedicines; 2023 Apr; 11(5):. PubMed ID: 37238918 [TBL] [Abstract][Full Text] [Related]
58. Longitudinal analysis of anti-SARS-CoV-2 neutralizing antibody (NAb) titers in vaccinees using a novel giant magnetoresistive (GMR) assay. Ng E; Choi C; Wang SX Sens Actuators B Chem; 2023 Jul; 387():133773. PubMed ID: 37056483 [TBL] [Abstract][Full Text] [Related]
59. The Influence of Booster Shot and SARS-CoV-2 Infection on the Anti-Spike Antibody Concentration One Year after the First COVID-19 Vaccine Dose Administration. Swadźba J; Anyszek T; Panek A; Chojęta A; Piotrowska-Mietelska A; Martin E Vaccines (Basel); 2023 Jan; 11(2):. PubMed ID: 36851157 [TBL] [Abstract][Full Text] [Related]
60. Serological Responses up to 9 Months following COVID-19 mRNA Vaccination in Residents and Health-Care Workers of Long-Term Care Facilities: A Multicenter Prospective Cohort Study in Northern Italy. Vicentini C; Zotti CM; Cornio AR; Garlasco J; Marengo N; Meddis D; Ditommaso S; Giacomuzzi M; Memoli G; Bordino V; Gianino MM; On Behalf Of The Collaborating Group Vaccines (Basel); 2022 Dec; 10(12):. PubMed ID: 36560593 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]